Extrapulmonary Tuberculoses and Rifampicin Resistance in St.Luke Catholic Hospital and Tullu Bollo Hospital, Oromia, Ethiopia.
No Thumbnail Available
Date
2018-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Addis Ababa Universty
Abstract
Background: Tuberculosis affects millions of peoples in the world which involves any organ system of the body. The extrapulmonary tuberculosis (EPTB) problem is increasing mainly due to drug resistant M. tuberculosis especially in developing countries. For the diagnosis of EPTB, GeneXpert has recently been developed for rapid detection of M.tuberclosis and rifampicin resistance. Assessing the prevalence of extrapulmonary tuberculosis provide effective patients management and help policy makers.
Objectives: To assess the magnitude of extrapulmonary tuberculosis and rifampicin resistance at St.Luke Catholic Hospital and Tullu Bollo Hospital, Oromia, Ethiopia.
Methods: A cross sectional study was conducted from March to August, 2017. A total of 310 body fluid specimens were collected and analyzed by gene Xpert. Ziehle-Nelson and Florescent microscopic examination were done for each specimen. Clinical history of all patients was reviewed for HIV. Binary and logistic regression was performed to assess the strength of associations between independent and dependent variables. Data entry and analysis was done using SPSS statistical software version 20. Results: Out of 310 body fluid specimens, 16.5% (n=51/310) were positive for MTB of which 3.9 %( n=2/51) specimens also exhibited resistance to RIF. About 3.2% (n=10/310) cases of GeneXpert MTB/RIF assay positive were ZN positive, 13.2% (n=41/310) cases of GeneXpert MTB/RIF assay positive were ZN negative and 6.8%(n=21/310) cases of GeneXpert MTB/RIF assay positive were FM positive, 9.7 % (n=30/310) cases of GeneXpert MTB/RIF assay positive were FM negative. A significant proportion of EPTB cases were also co-infected with HIV.
Conclusion: The prevalence of GeneXpert confirmed extra pulmonary tuberculosis infection was lower. Regular initiation and awareness for clinician about EPTB and its diagnostic tool is expected from health offices and stake holders. Further studies are required to clarify operational difficulty, challenges and limitations in rule-out GeneXpert MTB/RIF in current TB control/treatment algorithms in the country. Keywords: Extrapulmonary tuberculosis, Rifampicin resistance Oromia, Ethiopia